• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Genzyme Ventures

edit

Genzyme Ventures is a corporate venture capital fund dedicated to helping Genzyme Corporation achieve its strategic goals. Founded in 2001, the $100 million fund has a current portfolio of direct corporate investments and has taken LP positions in funds managed by life-science focused VC firms. Through its direct investments in private early-stage companies, the fund aims to forge relationships which may lead to larger collaborations in the future. Genzyme Ventures is able to leverage the entire Genzyme organization, including its global experience and expertise in R&D, reimbursement, and commercialization, to provide portfolio companies with invaluable advice and assistance. Its Limited Partnership investments provide insight into the broader healthcare innovation landscape.

Milestones

edit

• 
  Genzyme Ventures invested in TcLand Expression . (12/19/07)
  Posted 3/14/10 at 7:50pm via accessmylibrary.com
• 
  Genzyme Ventures invested in bluebird bio. (3/12/10)
  Posted 3/12/10 at 6:38pm via fiercebiotech.com
• 
  Genzyme Ventures invested in GlycoMimetics. (12/7/09)
  Posted 10/21/09 at 11:56pm via onbiovc.com
• 
  Genzyme Ventures invested in Fate Therapeutics. (11/16/09)
  Posted 11/16/09 at 11:35am via fatetherapeutics.com
• 
  Genzyme Ventures invested in Proteostasis Therapeutics. (8/25/08)
  Posted 6/21/09 at 11:40pm via reuters.com
• 
  Genzyme Ventures invested in KaloBios Pharmaceuticals. (12/22/08)
  Posted 6/14/09 at 11:02pm via kalobios.com
• 
  Genzyme Ventures invested in Sirtris Pharmaceuticals. (4/19/06)
  Posted 5/21/08 at 2:11pm via fiercebiotech.com
• 
  Genzyme Ventures — plans to build a manufacturing plant in Geel, Belgium (1/20/11)
  Posted 1/20/11 at 8:36am via masshightech.com

Investments

Videos

Sources

1. Genzyme expands Belgium manufacturing plant (masshightech.com) [edit]
2. Genetix raises $35M to advance gene therapies (fiercebiotech.com) [edit]
3. GlycoMimetics, Inc.: Series C $38M (onbiovc.com) [edit]
4. Fate Therapetucis (fatetherapeutics.com) [edit]
5. KaloBios Raises Additional $12 Million in Series D Venture Financing for a New Total of $32 Million (kalobios.com) [edit]
6. Proteostasis Therapeutics Secures a $45 Million Series A Financing to Develop Proteostasis Regulator(TM) Drugs (reuters.com) [edit]
7. TcLand expression's Series A adds 8m [euro] for biomarker work. (accessmylibrary.com) [edit]
8. Sirtris pockets $37M in venture funds (fiercebiotech.com) [edit]